SUBSTITUTED PYRAZOLO PIPERIDINE CARBOXYLIC ACIDS

The invention relates to substituted pyrazolo piperidine carboxylic acids, their salts and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular and cardiac diseases, preferably heart failure...

Full description

Saved in:
Bibliographic Details
Main Authors ORTEGA HERNANDEZ, NURIA, HOFMEISTER, LUCAS HUDSON, STELLFELD, TIMO, CANDISH, LISA, DIESKAU, ANDRE, SANDNER, PETER, BOULTADAKIS-ARAPINIS, MELISSA, WEBSTER, ROBERT ALAN, VAKALOPOULOS, ALEXANDROS, WUNDER, FRANK, SCHMECK, CARSTEN, COLLIN-KROPELIN, MARIE-PIERRE, MATHAR, ILKA, DIETZ, LISA
Format Patent
LanguageEnglish
French
Published 16.06.2022
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The invention relates to substituted pyrazolo piperidine carboxylic acids, their salts and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular and cardiac diseases, preferably heart failure with reduced and preserved ejection fraction (HFrEF, HFmrEF and HFpEF), hypertension (HTN), peripheral arterial diseases (PAD, PAOD), cardio-renal and kidney diseases, preferably chronic and diabetic kidney disease (CKD and DKD), cardiopulmonary and lung diseases, preferable pulmonary hypertension (PH), and other diseases, preferably neurodegenerative diseases and different forms of dementias, fibrotic diseases, systemic sclerosis (SSc), sickle cell disease (SCD), wound healing disorders such as diabetic foot ulcer (DFU). L'invention concerne des acides pyrazolo pipéridine carboxyliques substitués, leurs sels et leurs procédés de préparation, ainsi que leur utilisation pour la préparation de médicaments pour le traitement et/ou la prophylaxie de maladies, en particulier de maladies cardiovasculaires et cardiaques, de préférence l'insuffisance cardiaque avec une fraction à éjection réduite et préservée (HFrEF, HFmrEF et HFpEF), l'hypertension (HTN), des maladies artérielles périphériques (PAD, PAOD), des maladies cardio-rénales et rénales, de préférence des maladies rénales chroniques et diabétiques (CKD et DKD), des maladies cardio-pulmonaires et pulmonaires, de préférence l'hypertension pulmonaire (PH), et d'autres maladies, de préférence des maladies neurodégénératives et différentes formes de démences, des maladies fibrotiques, la sclérose systémique (SSc), la drépanocytose (SCD), les troubles de cicatrisation tels que l'ulcère du pied diabétique (DFU).
Bibliography:Application Number: CA20213204494